Exenatide
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
AstraZeneca · Phase 3 · Completed · Enrollment 119
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Exenatide once weekly (EQW ), one timepoint
- Dapagliflozin (DAPA), one timepoint
- EQW plus DAPA, one timepoint
- Dapagliflozin plus Glucophage (MET ER), one timepoint
- Phentermine /Topiramate (PHEN/ TPM) ER, one timepoint
- Exenatide once weekly (EQW ): week 24 3.8%
- Dapagliflozin (DAPA): week 24 1.5%
- EQW plus DAPA: week 24 6.9%
- Dapagliflozin plus Glucophage (MET ER): week 24 1.7%
- Phentermine /Topiramate (PHEN/ TPM) ER: week 24 8.1%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.